{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-sample-retention-and-destruction”
},
“headline”: “SOP for Sample Retention and Destruction”,
“description”: “This SOP defines procedures for the retention and destruction of biological samples collected in clinical trials, in compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements. It includes retention timelines, storage conditions, destruction certification, and regulatory alignment.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Sample Retention and Destruction

Purpose

The purpose of this SOP is to define procedures for the retention and destruction of biological samples collected during clinical trials. Proper retention ensures availability of samples for regulatory inspection, additional testing, and verification, while destruction safeguards confidentiality and subject rights once retention timelines expire.

Scope

This SOP applies to all clinical trial biological samples, including blood, urine, plasma, serum, tissue, genetic material, and pharmacokinetic specimens. It covers retention timelines, long-term storage, destruction certification, vendor qualification, and documentation requirements.

Responsibilities

• Sponsor: Defines retention timelines and destruction policies in protocols and contracts.
• Investigator: Ensures local sample storage complies with regulatory requirements.
• Laboratory Staff: Maintain freezer inventories and destruction logs.
• QA: Audits retention and destruction records for compliance.
• Vendors: Perform secure destruction of biospecimens and provide certificates.

Accountability

The Sponsor is accountable for ensuring retention and destruction practices meet global regulatory standards. The Investigator is accountable for proper handling at site level. QA is accountable for oversight and inspection readiness.

Procedure

1. Retention Timelines
1.1 Retain samples as per protocol or regulatory requirements:
– FDA: 2 years after marketing approval or trial discontinuation.
– EMA: Minimum 25 years for trial-related documents; samples per protocol.
– CDSCO: Minimum 5 years or as defined.
– WHO: 15 years or per sponsor policy.
1.2 Document retention period in Sample Retention Log (Annexure-1).

2. Storage Conditions
2.1 Store samples at validated conditions (−20°C, −80°C, or LN2).
2.2 Maintain Freezer Inventory Log (Annexure-2).
2.3 Monitor temperatures continuously and record daily checks.

3. Sample Release for Testing
3.1 Sponsor authorization required for secondary testing.
3.2 Record sample usage in Retained Sample Utilization Log (Annexure-3).

4. Sample Destruction
4.1 Once retention period expires, samples must be destroyed securely.
4.2 Destruction must follow validated methods (incineration, autoclaving, chemical neutralization).
4.3 Maintain Certificate of Destruction (Annexure-4).
4.4 Witness must be present and sign destruction logs.

5. Subject Withdrawal Requests
5.1 Destroy samples if subject withdraws consent for future use.
5.2 Record action in Withdrawal Sample Log (Annexure-5).

6. Documentation
6.1 All logs must be contemporaneous, legible, and complete.
6.2 Retain destruction certificates permanently in TMF.

Abbreviations

• SOP: Standard Operating Procedure
• QA: Quality Assurance
• TMF: Trial Master File
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• CDSCO: Central Drugs Standard Control Organization
• WHO: World Health Organization
• LN2: Liquid Nitrogen

Documents

1. Sample Retention Log (Annexure-1)
2. Freezer Inventory Log (Annexure-2)
3. Retained Sample Utilization Log (Annexure-3)
4. Certificate of Destruction (Annexure-4)
5. Withdrawal Sample Log (Annexure-5)

References

• ICH E6(R2/R3) – Biological Sample Management
• FDA – Retention and Destruction of Samples
• EMA – Sample Retention Guidelines
• CDSCO – Retention Requirements
• WHO – Retention and Destruction of Clinical Samples

Version: 1.0

Approval Section

Annexures

Annexure-1: Sample Retention Log

Annexure-2: Freezer Inventory Log

Annexure-3: Retained Sample Utilization Log

Annexure-4: Certificate of Destruction

Annexure-5: Withdrawal Sample Log

Revision History

For more SOPs visit: Pharma SOP